Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 143 No. 3536 (2013)

High rate of completion of preventive therapy for latent tuberculosis infection among asylum seekers in a Swiss Canton

  • Apostolos Sarivalasis
  • Patrick Bodenmann
  • Elisabeth Langenskiold
  • Caroline Lutchmaya- Flick
  • Oscar Daher
  • Jean-Pierre Zellweger
DOI
https://doi.org/10.4414/smw.2013.13860
Cite this as:
Swiss Med Wkly. 2013;143:w13860
Published
25.08.2013

Summary

BACKGROUND: Preventive treatment may avoid future cases of tuberculosis among asylum seekers. The effectiveness of preventive treatment depends in large part on treatment completion.

METHODS: In a prospective cohort study, asylum seekers of two of the Swiss Canton Vaud migration centres were screened with the Interferon Gamma Release Assay (IGRA). Those with a positive IGRA were referred for medical examination. Individuals with active or past tuberculosis were excluded. Preventive treatment was offered to all participants with positive IGRA but without active tuberculosis. The adherence was assessed during monthly follow-up.

RESULTS: From a population of 393 adult migrants, 98 (24.9%) had a positive IGRA. Eleven did not attend the initial medical assessment. Of the 87 examined, eight presented with pulmonary disease (five of them received a full course of antituberculous therapy), two had a history of prior tuberculosis treatment and two had contraindications to treatment. Preventive treatment was offered to 75 individuals (4 months rifampicin in 74 and 9 months isoniazid in one), of whom 60 (80%) completed the treatment.

CONCLUSIONS: The vulnerability and the volatility of this population make screening and observance of treatment difficult. It seems possible to obtain a high rate of completion using a short course of treatment in a closely monitored population living in stable housing conditions.

References

  1. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, Abubakar I, Lalvani A. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis. 2011.
  2. Horsburgh CR, Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350(20):2060–7.
  3. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-{gamma} release assays for the diagnosis of latent M. tuberculosis infection: A systematic review and meta-analysis. Eur Respir J. 2010.
  4. Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with m. tuberculosis: update 2010. Eur Respir J. 2010.
  5. Horsburgh CR, Jr., Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364(15):1441–8.
  6. Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179(11):1055–60.
  7. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999–2000. Am J Respir Crit Care Med. 2008;177(3):348–55.
  8. Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J. 2011;37(3):690–711.
  9. Horsburgh CR Jr., Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137(2):401–9.
  10. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12(11):1235–54.
  11. Eidlitz-Markus T, Zeharia A, Baum G, Mimouni M, Amir J. Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection. Chest. 2003;123(3):736–9.
  12. Sarivalasis A, Zellweger J, Faouzi M, Daher O, Deslarzes C, Bodenmann P. Factors associated with latent tuberculosis among asylum seekers in Switzerland: a cross-sectional study in Vaud County. BMC Infectious Diseases. 2012 ;12:285.
  13. Ligue Pulmonaire S. Manuel de la tuberculose (2e edit). Ligue Pulmonaire Suisse, http://www.tbinfo.ch, Berne, 2007.
  14. Hirsch-Moverman Y, Bethel J, Colson PW, Franks J, El-Sadr W. Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience. Int J Tuberc Lung Dis. 2010;14(9):1104–11.
  15. Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. Int J Tuberc Lung Dis. 2010;14(5):551–9.
  16. Fresard I, Bridevaux PP, Rochat T, Janssens JP. Adverse effects and adherence to treatment of rifampicine 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Swiss Med Wkly. 2011;141: w13240.
  17. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006;174(6):717–21.
  18. Marais BJ, van ZS, Schaaf HS, van AM, Gie RP, Beyers N. Adherence to isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child. 2006;91(9):762–5.
  19. Breuss E, Helbling P, Altpeter E, Zellweger JP. Screening and treatment for latent tuberculosis infection among asylum seekers entering Switzerland. Swiss Med Wkly. 2002;132(15-16):197–200.
  20. Racine-Perreaud E, Zellweger JP. Chimioth‚rapie antituberculeuse preventive chez 250 patients du Dispensaire antituberculeux de Lausanne. Schweiz Med Wschrift. 1994;124:705–11.
  21. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445–9.
  22. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689–97.
  23. Langenskiold E, Herrmann FR, Luong BL, Rochat T, Janssens JP. Contact tracing for tuberculosis and treatment for latent infection in a low incidence country. Swiss Med Wkly. 2008;138(5-6):78–84.
  24. Bodenmann P, Vaucher P, Wolff H, Favrat B, de Tribolet F, Masserey E, et al. Screening for latent tuberculosis infection among undocumented immigrants in Swiss healthcare centres; a descriptive exploratory study. BMC Infectious Diseases. 2009;9(1):34.
  25. MacIntyre CR, Plant AJ, Yung A, Streeton JA. Missed opportunities for prevention of tuberculosis in Victoria, Australia. Int J Tuberc Lung Dis. 1997;1:135–41.
  26. Mulder C, van Deutekom H, Huisman EM, Toumanian S, Koster BF, Meijer-Veldman W, et al. Role of the QuantiFERON(R)-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection. Eur Respir J. 2012;40(6):1443–9.
  27. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis. 2008;12(12):1352–64.

Most read articles by the same author(s)